The Promise of MCDA to Improve Equity in Value Assessment
In a commentary in AJMC, IVI examines how multi-criteria decision analysis has the potential to better understand and assess value for innovative cell and gene therapies which are transforming the lives of patients living with serious diseases. Read the full article here.
Can Depression Help Employers Improve Their Value Assessment Methods?
IVI’s Jennifer Bright and Mike Thompson of the National Alliance for Healthcare Purchasers share how employers can use depression as a “test case” for thinking about how to improve the value assessment process, so that we can apply a “purchaser-patient” lens up front. Read the full article on Employers Benefit News here.
Neumann and Co-authors Respond to ASCO Value Framework
In an article published in the Journal of Clinical Oncology, Peter Neumann and other members of ISPOR respond to ASCO’s revised framework for value assessment in cancer. Source: Journal of Clinical Oncology
Expanding Value Assessment Beyond Drugs
Jennifer Bright writes in Morning Consult that while we’ve made progress assessing the value of biopharmaceuticals, more focus is needed to develop bout transparent, patient-centered value assessment methods in healthcare technologies beyond drugs. Read the full article here.
What’s in Store for 2020?
Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip […]
The Ascendency of Value Assessment
Value assessment is a hot topic in healthcare. But how can it be improved so it’s more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains why we need data partners to catalyze improvement in value assessment. Read the article here.
IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA
IVI offered comments on ICER’s recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI’s comments raise a broader question about the relevance of the analysis to decision making. IVI writes […]
Top Three Questions Employers Need to Ask Benefits Consultants
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are getting the most value out of their consultants’ recommendations. Read the full article here.
How IVI is Bringing Value to Cancer Care
After the release of the public comments for IVI-NSCLC, Managed Healthcare Executive took a look at IVI’s open-source model focusing on non-small lung cancer and how it will bring healthcare executives insight into value that otherwise wouldn’t exist with traditional models. Read the full article here.
5 Steps to Build an Active Learning System for Value Assessment
In the wake of this year’s ISPOR conference, IVI’s Executive Director, Jennifer Bright, reflects on how to move value assessment from a static snapshot in time to an active learning approach. She discusses the following five steps to improving value assessment: Take the transparency challenge. Embrace flexibility. Allow for iteration. Improve incorporation of non-clinical data. […]